Yahoo Finance28d
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the Phase 2b study of SPN-820 ...
Yahoo Finance28d
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
Feb. 18, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous ...